[Prevention of chronic obstructive pulmonary disease exacerbations].
Identifieur interne : 000519 ( Main/Exploration ); précédent : 000518; suivant : 000520[Prevention of chronic obstructive pulmonary disease exacerbations].
Auteurs : Daniel Dusser [France]Source :
- Presse medicale (Paris, France : 1983) [ 2213-0276 ] ; 2008.
Descripteurs français
- KwdFr :
- Arrêter de fumer (MeSH), Broncho-pneumopathie chronique obstructive (prévention et contrôle), Broncho-pneumopathie chronique obstructive (psychologie), Broncho-pneumopathie chronique obstructive (économie), Bronchodilatateurs (usage thérapeutique), Coûts indirects de la maladie (MeSH), France (MeSH), Humains (MeSH), Oxygénothérapie (MeSH), Qualité de vie (MeSH), Thérapie respiratoire (MeSH), Éducation du patient comme sujet (MeSH).
- MESH :
- prévention et contrôle : Broncho-pneumopathie chronique obstructive.
- psychologie : Broncho-pneumopathie chronique obstructive.
- usage thérapeutique : Bronchodilatateurs.
- économie : Broncho-pneumopathie chronique obstructive.
- Arrêter de fumer, Coûts indirects de la maladie, France, Humains, Oxygénothérapie, Qualité de vie, Thérapie respiratoire, Éducation du patient comme sujet.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Bronchodilator Agents (therapeutic use), Cost of Illness (MeSH), France (MeSH), Humans (MeSH), Oxygen Inhalation Therapy (MeSH), Patient Education as Topic (MeSH), Pulmonary Disease, Chronic Obstructive (economics), Pulmonary Disease, Chronic Obstructive (prevention & control), Pulmonary Disease, Chronic Obstructive (psychology), Quality of Life (MeSH), Respiratory Therapy (MeSH), Smoking Cessation (MeSH).
- MESH :
- chemical , therapeutic use : Bronchodilator Agents.
- geographic : France.
- economics : Pulmonary Disease, Chronic Obstructive.
- prevention & control : Pulmonary Disease, Chronic Obstructive.
- psychology : Pulmonary Disease, Chronic Obstructive.
- Cost of Illness, Humans, Oxygen Inhalation Therapy, Patient Education as Topic, Quality of Life, Respiratory Therapy, Smoking Cessation.
Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) aggravate disease course, induce increased morbidity and mortality, impair quality of life, and raise the direct costs of COPD. Their prevention is essential and is an integral part of the COPD program defined by French health authorities for the 2005-2010 period. Both pharmacologic and nonpharmacologic approaches have been shown to be effective in preventing exacerbations, but these treatments are still underused and misused. Important nonpharmacologic therapies that directly decrease the risk of exacerbation or hospitalization include smoking cessation, oxygen therapy, pulmonary rehabilitation, and education. Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. Tiotropium reduces the frequency of exacerbation in both moderate and severe COPD. Inhaled glucocorticosteroid agents are not recommended alone. They must be prescribed only with a long-acting bronchodilator and only to patients with severe disease and repeated exacerbations. Influenza vaccination is recommended.
DOI: 10.1016/j.lpm.2008.08.003
PubMed: 18829252
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Prevention of chronic obstructive pulmonary disease exacerbations].</title><author><name sortKey="Dusser, Daniel" sort="Dusser, Daniel" uniqKey="Dusser D" first="Daniel" last="Dusser">Daniel Dusser</name><affiliation wicri:level="4"><nlm:affiliation>Faculté Cochin Port-Royal, Service de Pneumologie, Groupe Hospitalier Cochin Saint-Vincent-de-Paul, APHP, Université Paris Descartes, Paris Cedex 14, France. daniel.dusser@cch.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté Cochin Port-Royal, Service de Pneumologie, Groupe Hospitalier Cochin Saint-Vincent-de-Paul, APHP, Université Paris Descartes, Paris Cedex 14</wicri:regionArea><wicri:noRegion>Paris Cedex 14</wicri:noRegion><orgName type="university">Université Paris-Descartes</orgName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18829252</idno><idno type="pmid">18829252</idno><idno type="doi">10.1016/j.lpm.2008.08.003</idno><idno type="wicri:Area/Main/Corpus">000523</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000523</idno><idno type="wicri:Area/Main/Curation">000523</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000523</idno><idno type="wicri:Area/Main/Exploration">000523</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Prevention of chronic obstructive pulmonary disease exacerbations].</title><author><name sortKey="Dusser, Daniel" sort="Dusser, Daniel" uniqKey="Dusser D" first="Daniel" last="Dusser">Daniel Dusser</name><affiliation wicri:level="4"><nlm:affiliation>Faculté Cochin Port-Royal, Service de Pneumologie, Groupe Hospitalier Cochin Saint-Vincent-de-Paul, APHP, Université Paris Descartes, Paris Cedex 14, France. daniel.dusser@cch.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté Cochin Port-Royal, Service de Pneumologie, Groupe Hospitalier Cochin Saint-Vincent-de-Paul, APHP, Université Paris Descartes, Paris Cedex 14</wicri:regionArea><wicri:noRegion>Paris Cedex 14</wicri:noRegion><orgName type="university">Université Paris-Descartes</orgName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author></analytic><series><title level="j">Presse medicale (Paris, France : 1983)</title><idno type="eISSN">2213-0276</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bronchodilator Agents (therapeutic use)</term><term>Cost of Illness (MeSH)</term><term>France (MeSH)</term><term>Humans (MeSH)</term><term>Oxygen Inhalation Therapy (MeSH)</term><term>Patient Education as Topic (MeSH)</term><term>Pulmonary Disease, Chronic Obstructive (economics)</term><term>Pulmonary Disease, Chronic Obstructive (prevention & control)</term><term>Pulmonary Disease, Chronic Obstructive (psychology)</term><term>Quality of Life (MeSH)</term><term>Respiratory Therapy (MeSH)</term><term>Smoking Cessation (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Arrêter de fumer (MeSH)</term><term>Broncho-pneumopathie chronique obstructive (prévention et contrôle)</term><term>Broncho-pneumopathie chronique obstructive (psychologie)</term><term>Broncho-pneumopathie chronique obstructive (économie)</term><term>Bronchodilatateurs (usage thérapeutique)</term><term>Coûts indirects de la maladie (MeSH)</term><term>France (MeSH)</term><term>Humains (MeSH)</term><term>Oxygénothérapie (MeSH)</term><term>Qualité de vie (MeSH)</term><term>Thérapie respiratoire (MeSH)</term><term>Éducation du patient comme sujet (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bronchodilator Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Bronchodilatateurs</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost of Illness</term><term>Humans</term><term>Oxygen Inhalation Therapy</term><term>Patient Education as Topic</term><term>Quality of Life</term><term>Respiratory Therapy</term><term>Smoking Cessation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Arrêter de fumer</term><term>Coûts indirects de la maladie</term><term>France</term><term>Humains</term><term>Oxygénothérapie</term><term>Qualité de vie</term><term>Thérapie respiratoire</term><term>Éducation du patient comme sujet</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Exacerbations of chronic obstructive pulmonary disease (COPD) aggravate disease course, induce increased morbidity and mortality, impair quality of life, and raise the direct costs of COPD. Their prevention is essential and is an integral part of the COPD program defined by French health authorities for the 2005-2010 period. Both pharmacologic and nonpharmacologic approaches have been shown to be effective in preventing exacerbations, but these treatments are still underused and misused. Important nonpharmacologic therapies that directly decrease the risk of exacerbation or hospitalization include smoking cessation, oxygen therapy, pulmonary rehabilitation, and education. Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. Tiotropium reduces the frequency of exacerbation in both moderate and severe COPD. Inhaled glucocorticosteroid agents are not recommended alone. They must be prescribed only with a long-acting bronchodilator and only to patients with severe disease and repeated exacerbations. Influenza vaccination is recommended.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18829252</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-0276</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>11</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Prevention of chronic obstructive pulmonary disease exacerbations].</ArticleTitle><Pagination><MedlinePgn>1604-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lpm.2008.08.003</ELocationID><Abstract><AbstractText>Exacerbations of chronic obstructive pulmonary disease (COPD) aggravate disease course, induce increased morbidity and mortality, impair quality of life, and raise the direct costs of COPD. Their prevention is essential and is an integral part of the COPD program defined by French health authorities for the 2005-2010 period. Both pharmacologic and nonpharmacologic approaches have been shown to be effective in preventing exacerbations, but these treatments are still underused and misused. Important nonpharmacologic therapies that directly decrease the risk of exacerbation or hospitalization include smoking cessation, oxygen therapy, pulmonary rehabilitation, and education. Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. Tiotropium reduces the frequency of exacerbation in both moderate and severe COPD. Inhaled glucocorticosteroid agents are not recommended alone. They must be prescribed only with a long-acting bronchodilator and only to patients with severe disease and repeated exacerbations. Influenza vaccination is recommended.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dusser</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculté Cochin Port-Royal, Service de Pneumologie, Groupe Hospitalier Cochin Saint-Vincent-de-Paul, APHP, Université Paris Descartes, Paris Cedex 14, France. daniel.dusser@cch.aphp.fr</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Prévention des exacerbations de bronchopneumopathie chronique obstructive.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012138" MajorTopicYN="N">Respiratory Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016540" MajorTopicYN="N">Smoking Cessation</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>26</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18829252</ArticleId><ArticleId IdType="pii">S0755-4982(08)00490-9</ArticleId><ArticleId IdType="doi">10.1016/j.lpm.2008.08.003</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement><orgName><li>Université Paris-Descartes</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Dusser, Daniel" sort="Dusser, Daniel" uniqKey="Dusser D" first="Daniel" last="Dusser">Daniel Dusser</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000519 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000519 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18829252
|texte= [Prevention of chronic obstructive pulmonary disease exacerbations].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18829252" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeFranceV1
| This area was generated with Dilib version V0.6.35. |  |